Trovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers...
Read moreTrovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers...
Read moreAnnual Revenue
$ < 1M
Cardiff Oncology's revenue is the ranked 14th among it's top 10 competitors. The top 10 competitors average 119.1M. Over the last four quarters, Cardiff Oncology's revenue has decreased by 30.1%. Specifically, in Q3 2022's revenue was $ < 1M; in Q2 2022, it was $ < 1M; in Q1 2022, it was $ < 1M; in Q4 2021, Cardiff Oncology's revenue was $ < 1M.